BSECompany Update12 Aug 2026 · 12 Aug 2026, 05:07 pm

We hereby submit intimation regarding approval for Two new products in Ethiopia.

Speciality Medicines Ltd · 544738

✦ AI Summary▲ PositiveOrder Win

Speciality Medicines Ltd has received regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations, Olanzapine Tablets 5 mg and Diazepam Tablets 5 mg, taking its total registered product portfolio in the Ethiopian market to 12 formulations.

Analysis Scores

Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Speciality Medicines Ltd - 544738 - Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Approval For Two New Products In Ethiopia

Attachments (1)

📄

2fb8f869-81a0-4526-9dd9-fb22ecf0e9cd.pdf

pdf

Download →
View document text
Exporter & Trader of Speciality Medicines Date: 12/08/2026 BSE Limited. PJ Towers, Dalal Street, Mumbai – 400001 Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding Approval for Two New Products in Ethiopia Reference: Speciality Medicines Limited (Id: SPML; Code: 544738) Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable provisions, we wish to inform you that Speciality Medicines Limited, a speciality pharmaceutical company with a diversified export presence across regulated and semi-regulated global markets, today announced that it has received regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations - Olanzapine Tablets 5 mg (Olazyn 5) and Diazepam Tablets 5 mg (Diazem 5). With these approvals, the company’s total registered product portfolio in the Ethiopian market stands at 12 formulations, while its presence in Peru with 2 registered formulations, further strengthening its international product portfolio and continued progress in regulatory registrations across key export markets. A press release titled “Speciality Medicines Limited Secures Regulatory Approval for Two New Products in Ethiopia” is also being submitted to the Stock Exchange in connection with the aforesaid Approval. The above information is being submitted for the information of the Stock Exchange and the members of the Company. Kindly take the above information on record. Thanking you, Yours Faithfully, For, SPECIALITY MEDICINES LIMITED (Formerly Known as Speciality Medicines Private Limited) SUMIT GOYANI Whole-Time Director DIN: 07885780 Place: Mumbai SPECIALITY MEDICINES LIMITED (Formerly Known as Speciality Medicines Private Limited) CIN: L85300GJ2021PLC120022 Corp. Office : Unit 27, Ground Floor, Andheri Sainath Premises Co Soc, 20 Mahakali Caves Road, Andheri (East), Mumbai, Maharashtra, India, 400093 Regd. Office : 913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmedabad 380051, Gujarat, India +91 99242 03751 / 99242 43751 info@specialitymedicine.com www.specialitymedicine.com